Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gliotoxin is a sulfur-containing mycotoxin belonging to the epipolythiodioxopiperazine (ETP) class of natural products, characterized by a diketopiperazine core with a disulfide bridge. It is naturally produced by various fungi, most notably *Aspergillus fumigatus*, *Trichoderma virens*, and certain species of *Penicillium* and *Gliocladium*. Gliotoxin is primarily utilized as a research compound rather than a marketed pharmaceutical due to its significant systemic toxicity to mammalian cells. Its biological activity is pleiotropic, involving the inhibition of several key targets including the NF-κB signaling pathway, farnesyltransferase, geranylgeranyltransferase I, and NADPH oxidase. Research has explored its potential therapeutic applications as an antitumor agent (targeting breast, ovarian, and lung cancers), an antibacterial agent (active against MRSA), and an anti-fibrotic agent for liver fibrosis. Its mechanism of action often involves the modification of thiol groups in proteins and the generation of reactive oxygen species (ROS), leading to the induction of apoptosis in target cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gliotoxin.